Third Harmonic Bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a THRD research report →
Companywww.thirdharmonicbio.com
Third Harmonic Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications.
- CEO
- Natalie C. Holles
- IPO
- 2022
- Employees
- 31
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $242.79M
- P/E
- -8.35
- P/S
- 5058.07
- P/B
- 0.89
- EV/EBITDA
- 0.74
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 22.92%
- Op Margin
- -73239.58%
- Net Margin
- -60293.75%
- ROE
- -10.38%
- ROIC
- -12.75%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $45.47M · 247.51%
- EPS
- $1.09 · 239.74%
- Op Income
- $58.87M
- FCF YoY
- -67.59%
Performance & Tape
- 52W High
- $16.02
- 52W Low
- $3.18
- 50D MA
- $5.38
- 200D MA
- $7.01
- Beta
- 2.13
- Avg Volume
- 262.78K
Get TickerSpark's AI analysis on THRD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 11, 25 | Holles Natalie C. | other | 998,854 |
| Aug 11, 25 | Holles Natalie C. | other | 50,000 |
| Aug 11, 25 | Holles Natalie C. | other | 1,218,836 |
| Aug 11, 25 | Gladstone Michael | other | 43,584 |
| Aug 11, 25 | Murphy Christopher M. | other | 47,500 |
| Aug 11, 25 | Iwicki Mark T | other | 83,296 |
| Aug 11, 25 | Iwicki Mark T | other | 128,631 |
| Aug 11, 25 | Seidel Hans Martin | other | 85,753 |
| Aug 11, 25 | Seidel Hans Martin | other | 53,090 |
| Aug 11, 25 | Soloway Thomas P | other | 120,166 |
Our THRD Coverage
We haven't published any research on THRD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate THRD Report →